MEREO BIOPHARMA GROUP PLC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
MEREO BIOPHARMA GROUP PLC (MREO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.32M, a 36.22% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.60M, a 29.54% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.71M, a 1.44% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.06M, a 1.10% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $7.60M, a 2.81% increase from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $7.39M, a 50.08% increase from fiscal 2023.
- MEREO BIOPHARMA GROUP PLC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $4.92M, a 3.27% increase from fiscal 2022.
- MEREO BIOPHARMA GROUP PLC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.77M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.32M 10-Q · filed 2026-08-11 | $2.92M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $1.60M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $7.60M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $1.71M 10-Q · filed 2025-11-10 | $3.78M derived: sum of 2 quarters · filed 2026-08-11 | $6.05M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $2.06M 10-Q · filed 2026-08-11 | $4.34M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $2.28M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $7.39M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $1.74M 10-Q · filed 2025-11-10 | $3.83M derived: sum of 2 quarters · filed 2025-11-10 | $5.88M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $2.09M 10-Q · filed 2025-11-10 | $4.14M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $2.05M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $4.92M 10-K · filed 2025-03-26 | |||
| 2023-09-30 | $1.53M 10-Q · filed 2024-11-12 | $2.47M derived: sum of 2 quarters · filed 2024-11-12 | $4.11M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $943.00K 10-Q · filed 2024-11-12 | $2.58M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $1.64M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $4.77M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |